Icahn ally added to Forest board

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.

Icahn ally added to Forest board

Pursuant to an agreement with Carl Icahn and affiliated entities, Forest Laboratories' ($FRX) board of directors has appointed Vincent Intrieri as a new independent member of its board of directors. Intrieri sits on the boards of a number of companies, like Navistar International, in which Forest investor Carl Icahn has invested. Story


Forest Laboratories
Vincent Intrieri joins Forest's board of directors as an independent member.


Histogenics
MedImmune's Peter Greenleaf has been named the new CEO at Histogenics.

Biotech

> Peter Greenleaf has been named the new CEO at Histogenics, a regenerative medicine company. Item | Release

> Organovo Holdings, which makes 3-D bioprinting technology, appointed Tamar D. Howson as a member of its board of directors. Release

> Angus C. Russell joined the board of directors at Questcor Pharmaceuticals ($QCOR). Russell is recently retired as the CEO of Shire ($SHPG). Release

> Idenix Pharmaceuticals ($IDIX) appointed Charles Rowland, who previously held positions at Novartis ($NVS) and Bristol-Myers Squibb ($BMY), to the company's board of directors. Release

> StemCells ($STEM) appointed Eliseo Salinas as the company's executive vice president and head of research and development, Ann Tsukamoto as the executive vice president of scientific and strategic alliances, Nicki Vasquez as vice president of program and portfolio management, and Allyson Gage as senior director of clinical development. Release

> BioSurplus brought on Scott Meltzer as the company's director of specialized sales. Meltzer was owner and president of Laboratory Acquisition Services, which bought and sold used lab equipment. Release

> Dezima Pharma appointed Rob de Ree as its new CEO. De Ree comes from Amsterdam company BMEYE BV, where he was also CEO. Release

> Hurley Consulting Associates has appointed John Talian as vice president of regulatory affairs. Before joining Hurley Consulting, Talian was vice president, U.S. Head of Regulatory Affairs, Global Regulatory Affairs, at Bayer Healthcare Pharmaceuticals. Release

> Anthera Pharmaceuticals ($ANTH) has appointed May Liu as its senior vice president of finance and administration. Liu has served as the company's vice president of finance since January 2011. Release

> RRD International has appointed J. Scott Tarrant as its president. Tarrant joined RRD in 2010 as chief business officer. Release

> Regulus Therapeutics ($RGLS) has named Stelios Papadopoulos as chairman of its board of directors. Papadopoulos is a board member of several companies including Biogen Idec ($BIIB) and Exelixis ($EXEL), where he is chairman. Release

> MiRagen Therapeutics has appointed Christopher J. Morl as chief business officer and Aimee L. Jackson, director of target development. Morl has experience working for biopharma companies like Ambit Biosciences, Agensys and GlaxoSmithKline ($GSK). Jackson previously worked for Rosetta Inpharmatics/Merck ($MRK) in Seattle. Release

> OvaScience has named Mary Fisher, the CEO of Colorescience, to its board of directors. Release

Pharma

> MEI Pharma ($MEIP) has appointed Nick Glover to its board of directors. Glover was most recently president and CEO of YM BioSciences ($YMI), an oncology drug development company acquired by Gilead Sciences ($GILD) in February. Release

Diagnostics

> Diagnostics developer Rheonix named Frank Gill as the company's vice president of manufacturing. Release

Medical Devices

> Karyopharm Therapeutics has hired Paul Brannelly as senior vice president of finance and administration. Brannelly previously served as vice president of finance at Verastem ($VSTM). Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.